ClinicalTrials.gg
Enrolling by invitationNCT07741409Updated Nov 16, 2026

Povidone Iodine for Caries Prevention

A Phase 3 interventional study of Povidone Iodine 5% Soln,Top,Kit and Probiotics in Dental Caries, sponsored by Jeffrey A. Banas. Enrolling by invitation at 1 site in United States. Open to participants aged 1 Year to 3 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Jeffrey A. Banas · Phase 3, Interventional, and Prevention

How we know

Updated Nov 16, 2026Now Enrolling by invitationStart date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
174
Allocation
Randomized
Ages
1 Year to 3 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 194 studies in Dental Caries with a site in United States — 17 open to participants now, 20 under way, 3 of them phase 3. Dental Caries · United States.

Planned enrollment
46th of 169
174 · median 60
Started
2026
with 9 others
Phase 3
22 of 194
3 open now
Primary completion
2027-12
later than 12 of 19 live
Registered
191st of 194
by date

Among the 194 studies in Dental Caries with a site in United States, this one is the 46th largest by planned enrollment of the 169 interventional ones that give a count, is one of 10 that started in 2026, is one of 22 in phase 3, reaches primary completion later than 12 of the 19 other live ones, and was the 191st registered.

Dental Caries

1,176 studies on the registry are indexed under Dental Caries; 209 are open to participants now.

Browse Dental Caries studies →

Open to participants now

17 of the 194 studies in Dental Caries with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Dental Caries studies recruiting now, 18 (21%) set no upper age limit and 66 (77%) stop at 75 or younger; 60 take children under 18; 53 take healthy volunteers.

This study: 1 Year to 3 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Dental Caries with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if Povidone Iodine works to prevent tooth decay and suppress the mouth germs responsible for tooth decay. The main questions it aims to answer are:

  1. How will home use of Povidone Iodine, as an adjunct treatment to standard dental care, reduce the incidence of tooth decay?
  2. How will home use of Povidone Iodine reduce the mouth germs responsible for tooth decay?
  3. If Povidone Iodine use is accompanied by probiotic use, will its effectiveness be even better than Povidone Iodine alone?

Participants will:

  1. Provide a plaque sample at the beginning of the study.
  2. Swab their children's teeth once a week for one month and then monthly thereafter. Some participants may be asked to use probiotic drops nightly after brushing their teeth.
  3. Keep a record of compliance.
  4. Return every 6 months for a dental exam and to provide a plaque sample. Keep a diary of their symptoms and the number of times they use a rescue inhaler
Read the detailed description

Dental 'caries' is the term used to describe dental decay or 'cavities'. Dental caries can occur at any age but lesions prior to a child's 6th birthday qualify as 'early childhood caries' (ECC) and possibly as 'severe' early childhood caries (SECC) if the onset and severity meet definitions put forth by the American Academy of Pediatric Dentistry. ECC and SECC can have several unfortunate downstream consequences: pain, infection, nutritional deficiencies, poorer concentration in school, and social/cosmetic/financial concerns. Recent epidemiologic trends in ECC/SECC, reported by Kotha et al. (2022) based on data from the National Health and Nutrition Examination Survey (NHANES), have found little change in prevalence over the span from 2013 to 2018 with approximately 20% of children experiencing ECC by age 3 years with over half that percentage categorized as having SECC. Thus, there remains a critical need to improve prevention and treatment strategies.

Many variables can affect the likelihood of developing dental decay but prominent among these are excess consumption of sugary foods and drinks, inadequate oral hygiene, and poor access to dental care and oral health educational resources. Ultimately, microbes on the surface of teeth convert dietary sugar to acid that dissolves enamel thereby initiating and advancing decay. Brushing regularly with fluoridated toothpaste helps suppress the microbial population which decreases the acid challenge while fluoride promotes remineralization of enamel. Seeing a dentist regularly can ensure that any decay that develops is treated at its earliest stages thereby saving teeth.

While prevention strategies work well for many individuals, for a multitude of potential reasons they may prove inadequate for others. In particular, children with poor access to professional care or who are disadvantaged in other respects frequently fail to realize the benefits of the current standard of care.

The objective of this investigation is to test the effectiveness of povidone iodine (PI) as a home-administered preventive or treatment for dental caries that, unlike other treatment options, addresses the underlying cause - dental plaque that has an overabundance of strong acid-producing bacterial species. This imbalance of strong acid producers is referred to as a 'dysbiosis'. We will also test whether combining PI with probiotics - living microbes that can be used to boost health - will have a greater benefit than PI alone in maintaining or restoring a healthy microbial composition to dental plaque. We are in a unique position to leverage our access to children at high risk for decay to test multiple integrated hypotheses that we predict will result in more effective home dental care, and significant reductions in the incidence and severity of dental decay that is longer lasting than is possible with the current standard of care.

Despite tremendous advances in understanding how particular microbes in dental plaque lead to tooth decay, prevention and treatment options remain non-specific - dedicated to plaque control rather than to replacing the offending microbes with health-related species (correcting the dysbiosis). This limitation results in the chronic presence of an elevated microbial risk that likely proves most consequential in individuals with limited access to professional care and suboptimal oral hygiene habits. Importantly, PI is unique among current standard of care options because there is evidence that it not only can prevent caries but that it also attacks the microbial offenders that drive caries development. The addition of fluoride to water supplies and oral health care products was a game-changer. Protection appears to be due to improving the enamel remineralization/demineralization balance rather than any antimicrobial activity despite in vitro evidence of selective toxicity against S. mutans.

Consequently, fluoride is excellent at caries prevention (when available/applied in adequate amounts and frequency) but does not improve a dysbiotic plaque microbiome. Chlorhexidine, sometimes prescribed for individuals with rampant caries, is considered the 'gold-standard' of anti-plaque agents but a large NIDCR-sponsored study (Papas et al., 2012) found no greater protection against caries than the use of fluoride alone.

Additionally, chlorhexidine use does not appear to remedy a cariogenic dysbiosis. Silver products have a long history in dental treatment and have generated renewed interest in recent years. The strong staining properties of silver, however, limit its application. The preponderance of evidence does not support a role for silver in improving a cariogenic microbial dysbiosis but further investigation is necessary.

Iodine, like silver, has long been recognized for its antiseptic/antimicrobial properties. Combining iodine with povidone improves water solubility. Evidence to date suggests that PI offers the greatest breadth of desirable properties but additional investigation is necessary in order to make a strong case for widespread adoption by clinicians. This proposal seeks to document the effectiveness of home use of PI for providing long-term reduction in caries risk by reducing the microbial dysbiosis within cariogenic dental plaque.

Hypothesis(es) and objective(s): We hypothesize that home use of PI will reduce the incidence and severity of dental decay in a high-risk population of children. Though not a substitute for proper oral hygiene such as brushing twice a day for two minutes each, its application is so quick that compliance is more likely than engaging in routine, effective oral hygiene and it would likely boost the effectiveness of imperfect oral hygiene practices. We further hypothesize that PI has selective toxicity for oral pathogens and its use would improve the microbial make-up of dental plaque thereby helping sustain beneficial effects. Finally, we hypothesize that this latter property of PI can be combined with probiotic administration to elevate the beneficial effect.

Study Protocol:

Patient Pool: The patient pool will be children of ages 1 to 3 years old who receive care

through the Infant Oral Health clinic that is part of the Iowa City Women, Infant, Children (WIC) Program in Iowa City. The University of Iowa Department of Pediatric Dentistry has an ongoing collaboration with the IC-WIC to provide oral health care and sees 16 to 24 children per week (Weber-Gasparoni et al., 2010). The children are typically from low-income families and all are at high risk for decay. We estimate that we could recruit 3 to 5 subjects/week. To estimate the number of subjects necessary to obtain statistically significant results, we extrapolated from the results of Lopez et al. (2002) who used 10% povidone iodine and an outcome measure of new caries. Based on the

differences between treatment and placebo groups, 126 subjects (42 Group 1, PI; 42 Group 2, PI + probiotics; and 42 Group 3, placebo) would give 80% power to determine a statistical difference in caries outcome with an alpha error of 0.05. To meet this number, we will enroll 174 subjects to account for an estimated 27% annual attrition.

Subjects will be randomly assigned to Groups 1, 2 or 3. However, if a subject consents to use PI but not probiotics, their assignment will be to either Group 1 or Group 3. We anticipate completing enrollment during year 1 of the study but have reserved 18 months to meet the recruitment goal. We also want to make clear that Group 3 will be the placebo group for the Group 1 iodine treatment. After considerable contemplation, we decided against including a strict placebo group for the probiotic administration. We considered having Group 3 use both the PI placebo and probiotic placebo but that would 'muddy' the analytical comparison with Group 1 (PI alone). Including another distinct placebo group would add considerable expense to the project that might not be justified if compliance with a daily regimen turned out to be low. As designed, we feel this project will yield strong data for the efficacy of home use of PI. The inclusion of a probiotic group has the potential to add significant insight into the mechanism by which PI exerts any observed benefit, or it may offer a lesson in the limits of compliance for any sort of daily oral health promoting regimen.

Enrollment and Visit Protocols: Pediatric Dental Residents will be the practitioners

treating the prospective participants. They will be calibrated with respect to caries scoring (ICDAS) prior to initiating the study. Once it is determined that the subjects satisfy the inclusion criteria (child of appropriate age; no imminent plans to relocate), they will follow an IRB-approved recruitment/enrollment protocol that will also determine

if any exclusion criteria (thyroid condition; antibiotic usage in the prior 3 months) apply. Once informed consent is obtained, the current caries status will be recorded and a pooled plaque sample will be taken using a sterile foam-tipped applicator (Puritan®) and swabbing all exposed tooth surfaces. The study coordinator will provide the practitioner with PI (Povi-One povidone iodine unit dose kit; Elevate Oral Care®), PI and probiotic drops (Prodentis by BioGaia), or placebo (colored tea for PI). The practitioner will apply the PI treatment onto the teeth of the participant and instruct them in home use. For participants given probiotic, verbal instructions will be provided to administer the drops once a day after brushing before bedtime. While this protocol precludes keeping practioners blinded with respect to the intervention, only the study coordinator will keep a record of the participants' group assignment so that practioners will not have access to group assignment records at follow-up appointments thereby minimizing the possibility of bias in subsequent caries evaluations. The PI protocol will be one application per week for one month and then once a month thereafter. Probiotic application will be daily. The concentration of the povidone iodine will be 5% and the maximum dose of probiotic will be 5 drops. The amount disbursed in an application and the frequency of application will be well within the safety margins for iodine exposure (Frank et al., 2020). Subjects will receive reminders ahead of a scheduled home application of PI via text message or communication method of choice to help ensure compliance. Subjects will also have the opportunity to reply to the messaging so that compliance can be tracked and/or keep a home diary of compliance and personal oral hygiene habits (How many times per day/week do the children brush? Themselves or by parents? Does the toothpaste contain fluoride?). At each 6-month follow-up

appointment, subjects will again have their caries status recorded and provide a pooled-plaque sample. They will also be asked questions related to use of antibiotics during the period between baseline and follow-up appointments. Maximal duration of participation for any subject will be 1 year.

Processing of Plaque Samples for Microbiome Analysis: Pooled plaque samples will be

collected as described above. The foam tip of the applicator will be broken off into 300ul RNAlater™ (Invitrogen) for transport to lab and isolation of DNA using the Qiagen DNeasy PowerLyzer PowerSoil Kit. The DNA that is recovered contains strands from all the microbes present in the sample. Technology allows the DNA to be sequenced and computational software is capable of analyzing the sequences and providing a breakdown of the proportional representation of the different types of microbes present. To accomplish this, the DNA samples will be sent to LC Sciences (Houston, TX) for the sequencing and microbial data analysis. [For those technically inclined, the 16S sequencing primers will target the V3 and V4 regions. The resulting 465bp amplicon will be sequenced on a NovaSeq platform with 250bp paired-end reads. Raw data files will be obtained in FASTQ format, overlapping sequences merged, screened for data quality and chimera filtered. The algorithm DADA2 will then be applied to generate representative sequences and construction of Amplicon Sequence Variant tables that will be the basis for analyses of diversity and differential abundance analyses.

Taxonomy will be assigned using the QIIME2 naïve bayes classifier (Bokulich et al., 2018) trained on the Human Oral Microbiome Database (HOMD) v15.23].

Previous studies have demonstrated that treatment with 10% PI can reduce salivary/plaque levels of the highly acidogenic bacterial species Streptococcus mutans (Amin et al., 2004; Simratvir et al., 2010) but further substantiation including effects on the totality of the oral microbial population are warranted. We recently completed a longitudinal study focusing on the microbial changes that preceded a diagnosis of ECC (unpublished data) and found that S. mutans appeared to be the main driver or major contributor in about three-quarters of the children. In the other 25% who developed caries, it appeared that non-mutans acidogenic species or the loss of base-producing species were the major drivers. Therefore, our microbiome analysis will focus on S. mutans as well as on changes in the representation of key genera that are health related (Neisseria, Haemophilus) or caries related (Actinomyces, Prevotella, Kingella, Candida).

Data Analyses: Our data analyses will focus on answering three main questions: 1) did

home use of PI reduce caries incidence and severity?; 2) did home use of PI reduce the presence in dental plaque of microbial species most associated with dental decay?; and 3) did a daily regimen of probiotics enhance the effectiveness of the PI treatments by further reducing caries incidence/severity and the presence of decay-associated microbes? To answer each of these questions, caries rates and microbial composition outcomes from Group 3 (placebo) will be compared with Groups 1 (PI) and 2 (PI + probiotic), individually and in combination. Outcomes from Groups 1 and 2 can also be compared directly. We expect to use ANOVA for statistical analysis but will consult with a biostatistician to ensure that all analyses are experimentally appropriate and valid.

The analyses described above will provide answers to our three main questions and directly address the hypotheses being tested. Our data on compliance will provide perspective for these outcomes. We anticipate that home use of PI is quick and simple enough to elicit good compliance. We are less sure of what to expect with the probiotic. On the one hand, administration (5 drops) is quicker than brushing one's teeth (though recommended use is after brushing). On the other hand, our study groups may not be particularly proficient in adhering to recommended oral hygiene practices. Overall, we expect the PI to be protective to a significant degree regardless of personal daily oral hygiene habits. However, we expect that the magnitude of protection will improve in direct proportion to the frequency of personal oral hygiene, including compliance of probiotic use.

03

Conditions studied

  • Dental Caries

Browse trials for

Keywords

  • Dental Caries
  • Povidone Iodine
  • Probiotics
04

Who can participate

Ages eligible
1 Year to 3 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1 to 3 years of age
  • No plans to relocate in the next 12 months

Exclusion criteria

Exclusion Criteria

  • Thyroid condition
  • Antibiotic usage in the prior 3 months
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
174 participants (estimated)

Study arms

  • Experimental
    PI Alone

    This arm will be Povidone Iodine alone.

    Drug: Povidone Iodine 5% Soln,Top,Kit

  • Active comparator
    PI plus Probiotics

    This arm will determine if/how well probiotics improve the effect of the Povidone Iodine

    Drug: Povidone Iodine 5% Soln,Top,Kit · Dietary Supplement: Probiotics

  • Placebo comparator
    Placebo

    Placebo for the Povidone Iodine

    Drug: Placebo

Interventions

  • DrugPovidone-IodineStudies of Povidone-IodinePovidone-Iodine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Home use of Povidone Iodine administered by swabbing teeth; weekly for the 1st month, monthly thereafter.

  • Dietary supplementProbiotics

    Home use of Povidone Iodine coupled with daily use of a probiotic.

  • DrugPlacebo

    Placebo for the Povidone Iodine

06

What researchers measure

Primary outcomes

  1. Prevention of Dental Caries

    Change in the incidence of dental caries compared to placebo

    Time frame: Minimum 6 months; maximum 12 months

Secondary outcomes

  1. Microbiome

    Change in the cariogenic potential of the plaque microbiome compared to the placebo.

    Time frame: Minimum 6 months; maximum 12 months

07

Study locations

1 site
08

References and documents

Publications

  • Milgrom P, Tut O, Rothen M, Mancl L, Gallen M, Tanzer JM. Addition of Povidone-Iodine to Fluoride Varnish for Dental Caries: A Randomized Clinical Trial. JDR Clin Trans Res. 2021 Apr;6(2):195-204. doi: 10.1177/2380084420922968. Epub 2020 May 21. PubMed 32437626 ↗
  • Lyashenko C, Herrman E, Irwin J, James A, Strauss S, Warner J, Khor B, Snow M, Ortiz S, Waid E, Nasry B, Chai J, Choong C, Palmer E, Kutsch K, Forsyth A, Choi D, Maier T, Machida CA. Adjunctive dental therapies in caries-active children: Shifting the cariogenic salivary microbiome from dysbiosis towards non-cariogenic health. Hum Microb J. 2020 Dec;18:100077. doi: 10.1016/j.humic.2020.100077. Epub 2020 Aug 31. PubMed 34485763 ↗
  • Li Y, Tanner A. Effect of Antimicrobial Interventions on the Oral Microbiota Associated with Early Childhood Caries. Pediatr Dent. 2015 May-Jun;37(3):226-44. PubMed 26063552 ↗
  • Muntean A, Mzoughi SM, Pacurar M, Candrea S, Inchingolo AD, Inchingolo AM, Ferrante L, Dipalma G, Inchingolo F, Palermo A, Bordea IR. Silver Diamine Fluoride in Pediatric Dentistry: Effectiveness in Preventing and Arresting Dental Caries-A Systematic Review. Children (Basel). 2024 Apr 22;11(4):499. doi: 10.3390/children11040499. PubMed 38671716 ↗
  • Papas AS, Vollmer WM, Gullion CM, Bader J, Laws R, Fellows J, Hollis JF, Maupome G, Singh ML, Snyder J, Blanchard P; PACS Collaborative Group. Efficacy of chlorhexidine varnish for the prevention of adult caries: a randomized trial. J Dent Res. 2012 Feb;91(2):150-5. doi: 10.1177/0022034511424154. Epub 2011 Dec 7. PubMed 22156917 ↗
  • Bokulich NA, Kaehler BD, Rideout JR, Dillon M, Bolyen E, Knight R, Huttley GA, Gregory Caporaso J. Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2's q2-feature-classifier plugin. Microbiome. 2018 May 17;6(1):90. doi: 10.1186/s40168-018-0470-z. PubMed 29773078 ↗
  • Sulyanto RM, Beall CJ, Berger MT, Goodell CP, Koo S, Candamo F, Dickson JR, Kang M, Ho SP, Ng MW, Hashmi SB, Leys EJ, Griffen AL. Silver diamine fluoride alters microbial communities in subsurface dentin. JADA Found Sci. 2022 Feb 8;1:100004. doi: 10.1016/j.jfscie.2021.100004. eCollection 2022. PubMed 42238656 ↗
  • Zhang JS, Chen Z, Chu CH, Yu OY. Effect of silver diamine fluoride upon the microbial community of carious lesions: A scoping review. J Dent. 2023 Jul;134:104554. doi: 10.1016/j.jdent.2023.104554. Epub 2023 May 21. PubMed 37220834 ↗
  • Weber-Gasparoni K, Kanellis MJ, Qian F. Iowa's public health-based infant oral health program: a decade of experience. J Dent Educ. 2010 Apr;74(4):363-71. PubMed 20388808 ↗
  • Ribeiro AA, Paster BJ. Dental caries and their microbiomes in children: what do we do now? J Oral Microbiol. 2023 Apr 10;15(1):2198433. doi: 10.1080/20002297.2023.2198433. eCollection 2023. PubMed 37056224 ↗
  • Mitwalli H, Mourao MDA, Dennison J, Yaman P, Paster BJ, Fontana M. Effect of Silver Diamine Fluoride Treatment on Microbial Profiles of Plaque Biofilms from Root/Cervical Caries Lesions. Caries Res. 2019;53(5):555-566. doi: 10.1159/000499578. Epub 2019 May 28. PubMed 31137026 ↗
  • Mei ML, Yan Z, Duangthip D, Niu JY, Yu OY, You M, Lo ECM, Chu CH. Effect of silver diamine fluoride on plaque microbiome in children. J Dent. 2020 Nov;102:103479. doi: 10.1016/j.jdent.2020.103479. Epub 2020 Sep 17. PubMed 32950631 ↗
  • Lopez L, Berkowitz R, Spiekerman C, Weinstein P. Topical antimicrobial therapy in the prevention of early childhood caries: a follow-up report. Pediatr Dent. 2002 May-Jun;24(3):204-6. PubMed 12064491 ↗
  • Kotha A, Vemulapalli A, Mandapati SR, Aryal S. Prevalence, Trends, and Severity of Early Childhood Caries in The United States: National Health and Nutritional Examination Survey Data 2013 to 2018. Pediatr Dent. 2022 Jul 15;44(4):261-268. PubMed 35999681 ↗
  • Frank S, Capriotti J, Brown SM, Tessema B. Povidone-Iodine Use in Sinonasal and Oral Cavities: A Review of Safety in the COVID-19 Era. Ear Nose Throat J. 2020 Nov;99(9):586-593. doi: 10.1177/0145561320932318. Epub 2020 Jun 10. PubMed 32520599 ↗
  • Simratvir M, Singh N, Chopra S, Thomas AM. Efficacy of 10% Povidone Iodine in children affected with early childhood caries: an in vivo study. J Clin Pediatr Dent. 2010 Spring;34(3):233-8. doi: 10.17796/jcpd.34.3.l552816527xtv122. PubMed 20578661 ↗
  • Amin MS, Harrison RL, Benton TS, Roberts M, Weinstein P. Effect of povidone-iodine on Streptococcus mutans in children with extensive dental caries. Pediatr Dent. 2004 Jan-Feb;26(1):5-10. PubMed 15080351 ↗

Individual participant data

Plan to share: No — Confidentiality of participants

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2027, 14 months after the start.

Of 18 phase 3 interventional studies under Dental Caries, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 26. This study's planned 14 months is close to that.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2026
First posted
Aug 3, 2026
StartActual
Oct 12, 2026was Aug 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 30, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Nov 16, 2026
Start date
Aug 3, 2026→Oct 12, 2026 (actual)
Nov 16, 2026
Contact
No study contact listed any more: removed j•••@uiowa.edu · •••9911
Nov 16, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of Iowa College of Dentistry · Iowa City, United StatesContact removed j•••@uiowa.edu · •••9911Contact removed m•••@uiowa.edu · •••7439
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Not yet recruiting→Enrolling by invitation
    Start date Aug 3, 2026→Oct 12, 2026 (now actual)
    Contact No study contact listed any more: removed j•••@uiowa.edu · •••9911
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Iowa College of Dentistry · Iowa City, United StatesContact removed j•••@uiowa.edu · •••9911Contact removed m•••@uiowa.edu · •••7439
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07741409
Lead sponsor
Jeffrey A. Banas
Responsible party
Jeffrey A. Banas (Associate Dean, University of Iowa) — Sponsor-investigator
First posted
Aug 3, 2026
Start date
Oct 12, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Povidone-Iodine

Start the discussion